Business
Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis
For media and investors only Researchers identified variants which may cause activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)Results enable clinical genetic testing labs to appropriately reclassify VUSs, accelerating the path to a definitive APDS diagnosis for many patientsFindings reveal APDS may be more prevalent than previously estimatedWebcast to take place on Monday, June 30, 2025, at 16:30 CEST / 10:30 EDT Leiden, the Netherlands, June 24, 2025: Pharming Group N.V. (“Pharm
About this update from Pharming Group Nv
[{"type":"image","alt":"Pharming Group N.V.","displaySize":"","headline":null,"caption":"Pharming Group N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/e33000c1e8641d4ca14a349a419f6745"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6VI_P53XoKPQr35Rp9bMIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e33000c1e8641d4ca14a349a419f6745","width":300,"height":102}},"lazy":false},{"type":"text","content":"For media and investors only","length":28,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Researchers identified variants which may cause activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)","length":113,"tagName":"p"}]},{"val":[{"type":"text","content":"Results enable clinical genetic testing labs to appropriately reclassify VUSs, accelerating the path to a definitive APDS diagnosis for many patients","length":149,"tagName":"p"}]},{"val":[{"type":"text","content":"Findings reveal APDS may be more prevalent than previously estimated","length":68,"tagName":"p"}]},{"val":[{"type":"text","content":"Webcast to take place on Monday, June 30, 2025, at 16:30 CEST / 10:30 EDT","length":73,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":403,"olType":false},{"type":"text","content":"Leiden, the Netherlands, June 24, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces it will host a webcast for investors and analysts featuring Joshua Milner, MD, an internationally renowned immunologist, to discuss the findings of a recent study published in the peer-reviewed journal Cell.","length":348,"tagName":"p"},{"type":"text","content":"The study titled “Scalable generation and functional classification of genetic variants in inborn errors of immunity for improved clinical diagnosis and management” was led by Zachary Walsh, MD/PhD candidate, Dr. Milner and Benjamin Izar, MD, PhD of Columbia University. The publication details significant advances in diagnosing inborn errors of immunity, also known as primary immune disorders. The researchers’ approach helps resolve a major limit to interpretation of genetic testing that often yields variants of uncertain significance (VUS) when evaluating such disorders, including activated ...